Event Details

Investor Breakfast 2019

Dec 5, 2019

Add to Outlook

Add to Google Calendar

Location

New York, NY

Press Releases View all

September 25, 2019

BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

September 25, 2019

BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

September 3, 2019

BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

Upcoming Events View all